Invited Speaker ESA-SRB-NZSE-CaSR 2026 in conjunction with ENSA

Denosumab withdrawal - preventing the reboundĀ  (146781)

Mike Lin 1
  1. Endocrinology & Metabolism Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia

This case-based presentation outlines the key nursing considerations for patients receiving denosumab, including the importance of administering injections on time, recognising the risks associated with delayed or discontinued treatment, and educating patients that denosumab should not be stopped without an appropriate exit strategy to reduce the risk of rebound vertebral fractures.